According to the latest Australian pharmacy sales data to June, published by market research company IRi, Hylo-Forte generated more than $8.9 million in sales, $3.3 million more than the previous year when it placed fourth.This year’s figure represents 9.6% of all eye lubricant sales in Australia, which totaled $93.5 million in the past year. Hylo-Forte is designed for severe or chronic dry eye and post-operative use. Hylo-Fresh, a lower dosage product for mild to moderate dry eye, placed 11th overall with $2.6 million in sales.{{quote-A:R-W:400-I:2-Q:“We are seeing the relative sales position for NovaTears being even further ahead than Hylo-Forte was at the same time of its life cycle”-who:Hartley Atkinson, AFT}}Meanwhile, Alcon Laboratories’ Systane Ultra Eye Drop 10ml – last year’s category leader – and Systane Lub Eye Drop 15ml were the second and third highest earners respectively. They produced $8.8 million (+16%) and $6.2 million (–8%) in sales. Systane Ultra Eye Drop 24×0.4ml came in fifth with sales of $4.3 million.For AFT Pharmaceuticals, the success of Hylo-Forte follows the 2018 launch of the non-aqueous, preservative-free eye lubricant NovaTears, which has itself moved into the top 40 selling eye lubricant products, generating $556,000.Within the latest quarter alone, NovaTears sales have exceeded 1700% compared with the same period in 2018.
“We are seeing the relative sales position for NovaTears being even further ahead than Hylo-Forte was at the same time of its life cycle,” AFT CEO Dr Hartley Atkinson said.“This bodes well for the future potential of this unique patented product – which is specifically designed for Evaporative Dry Eye – and ultimately strengthens our over-the-counter eye care portfolio in Australia. More reading:Dry eye set to fuel eyecare explosion
